The objective of the LESS-VT Clinical Trial is to demonstrate that substrate ablation with the FlexAbility SE catheter is safe and effective in reducing the occurrence of MMVT in patients in whom VT recurs despite antiarrhythmic drug therapy or when AAD are not tolerated or desired.
Not Applicable - Describes studies without FDA-defined phases, including studies of devices or behavioral interventions.
University of Colorado Hospital
Wendy Tzou, MD, FACC, FHRS
Protocol Number: 18-1148
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers